Clinical Trial Update: A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and in combination with ipilimumab, nivolumab, or cemiplimab for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• B-cell Non-hodgkin Lymphoma
• Histiocytic and Dendritic Cell Neoplasm
• Mycosis Fungoides
• Myelodysplastic Syndrome
• Plasma Cell Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Libtayo (cemiplimab)
• OPDIVO (nivolumab)
• VSV-hIFNβ-NIS (vesicular stomatitis virus-based vaccine expressing IFN-β and NIS)
• Yervoy (ipilimumab)

Snippet

Sponsor: Mayo Clinic | Conditions: B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Status: RECRUITING